Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results, Misses Estimates By $9.37 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) issued its quarterly earnings results on Friday. The company reported ($19.28) EPS for the quarter, missing the consensus estimate of ($9.91) by ($9.37), Zacks reports. The company had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $3.50 million.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $0.45 on Monday. The stock has a market cap of $7.81 million, a P/E ratio of 0.00 and a beta of 2.12. The stock has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $5.43. The company has a current ratio of 1.47, a quick ratio of 0.87 and a debt-to-equity ratio of 0.06. Tonix Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $32.32.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TNXP shares. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Saturday. They set a “sell” rating for the company. Alliance Global Partners raised their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.